Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Liabilities: 2022-2025

Historic Total Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $97.6 million.

  • Taysha Gene Therapies' Total Liabilities rose 6.72% to $97.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.6 million, marking a year-over-year increase of 6.72%. This contributed to the annual value of $88.8 million for FY2024, which is 9.16% down from last year.
  • Taysha Gene Therapies' Total Liabilities amounted to $97.6 million in Q3 2025, which was up 15.32% from $84.6 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Total Liabilities high stood at $244.9 million for Q3 2023, and its period low was $83.3 million during Q1 2025.
  • Moreover, its 3-year median value for Total Liabilities was $97.6 million (2025), whereas its average is $110.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first spiked by 144.05% in 2023, then slumped by 62.67% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Total Liabilities (Quarterly) stood at $125.3 million in 2022, then declined by 21.97% to $97.8 million in 2023, then dropped by 9.16% to $88.8 million in 2024, then increased by 6.72% to $97.6 million in 2025.
  • Its Total Liabilities was $97.6 million in Q3 2025, compared to $84.6 million in Q2 2025 and $83.3 million in Q1 2025.